



Paris, 3rd February 2011, 8.45 am

## **AB Science obtains a bank loan of 1.7M€ guaranteed by Oseo**

**AB Science SA** (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today to have obtained a credit line of €1.7 million, running until February 2016.

This credit line, received from the bank Neuflyze OBC (group ABN Amro) and BNP Paribas, has a 5 year term, starting from the date of contract signature, with a 2 year differed payment period. It is counter guaranteed by Oseo at 60%.

This credit line is aimed at financing projects supporting the growth of the company.

Laurent Guy, CFO of AB Science declared « *This financing is non dilutive and will be used to finance projects supporting the growth of AB Science. We wish to thank our bank partners as well as Oseo, who has been working alongside AB Science since the beginning, for their confidence and renewed support.* ».

### **About AB Science**

Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. Masitinib, a lead compound, has already been registered in veterinary medicine in Europe and in the USA, and is pursuing nine phase 3 studies in human medicine, including five studies on-going in pancreatic cancer, GIST, in metastatic melanoma expressing JM mutation of c-Kit, in mastocytosis, and severe persistent asthma.

Further information is available on AB Science's website: [www.ab-science.com](http://www.ab-science.com)

*This document contains prospective information. No guarantee can be given as for the realisation of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.*

\* \* \*

AB Science - Financial Communication & Press Relations

**Citigate**  
**Dewe Rogerson**

Contacts Citigate Dewe Rogerson :  
Agnès Villeret - Tel: +33 1 53 32 78 95 - [agnes.villeret@citigate.fr](mailto:agnes.villeret@citigate.fr)